# IMMUNOBIL (NCT03704480)

> Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.

No report yet. It can be ordered.

- Drugs tested: durvalumab plus tremelimumab; durvalumab plus tremelimumab plus paclitaxel
- Indication: advanced biliary tract carcinoma after platinum-based chemotherapy failure

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03704480
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
- Conditions: Advanced Biliary Tract Carcinoma
- Interventions: Durvalumab; Tremelimumab
- Enrollment: 106
- Primary outcome: Overall Survival (OS) in amended Arm A

## Indexed commentary on IMMUNOBIL so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=immunobil-nct03704480